|
|
|
FY 2021
|
|
|
Q4 2021
|
|
|
|
|
Actual %
|
CER %
|
|
Actual %
|
CER %
|
|
|
$m
|
Change
|
change
|
$m
|
Change
|
change
|
- Product
Sales
|
|
36,541
|
41
|
38
|
11,498
|
64
|
65
|
- Collaboration
Revenue
|
|
876
|
20
|
20
|
513
|
29
|
29
|
Total
Revenue
|
|
37,417
|
41
|
38
|
12,011
|
62
|
63
|
Reported EPS
|
|
$0.08
|
(97)
|
(84)
|
$(0.22)
|
n/m6
|
n/m
|
Core
EPS
|
|
$5.29
|
32
|
37
|
$1.67
|
56
|
74
|
FY 2021
|
Metric
|
Reported
|
Reported change
|
Core
|
Corechange
|
|
Comments13
|
Total Revenue
|
$37,417m
|
41% increase (38% CER)
|
$37,417m
|
41% increase (38% CER)
|
|
See
Total Revenue commentary above
|
Gross Profit Margin14
|
66.0%
|
14 percentage point decline(13 at CER)
|
74.2%
|
6 percentage point decline(5 at CER)
|
|
+ Contribution
of Alexion
+ Increasing
mix of oncology sales
‒ Vaxzevria revenues
in 2021
‒ China
impact of NRDL and VBP
‒ Increasing
impact from profit-sharing arrangements
‒ Reported
impacted by unwind of Alexion inventory fair value
adjustment
|
R&D Expense
|
$9,736m
|
62% increase
(59% CER)
|
$7,987m
|
36% increase
(33% at CER)
|
|
+ Increased
investment in pipeline
+ COVID-19
medicines investment and pharmacovigilance
+ Addition
of Alexion R&D
+ 14
positive Phase III readouts in 2021
+ Reported
also impacted by $1,464m of impairments
|
SG&A Expense
|
$15,234m
|
35% increase
(32% at CER)
|
$11,104m
|
19% increase
(15% at CER)
|
|
+ Investments
in multiple launches
+ Addition
of Alexion
+ Expansion
in Emerging Markets
+ Reported
also impacted by amortisation related to Alexion acquisition, $338m
of restructuring and $603m of impairments
|
Other Operating Income15
|
$1,492m
|
2% decrease
(4% at CER)
|
$1,492m
|
3% decrease
(4% at CER)
|
|
= Divestment
gains at a similar level to FY 2020. See Table 38
|
Operating Margin
|
2.8%
|
17 percentage point decline(15 at CER)
|
26.5%
|
1 percentagepoint decline
(1 increase at CER)
|
|
See
Gross Margin and Expenses commentary above
|
Net Finance Expense
|
$1,257m
|
3% increase
(2% at CER)
|
$862m
|
10% increase
(11% at CER)
|
|
+ Alexion
debt financing costs
‒ Reported
impacted by lower discount unwind on acquisition-related
liabilities
|
Tax Rate
|
143%
|
n/m
|
17%
|
3 percentagepoint decrease
|
|
‒ Benefit
from non-taxable gain on the Viela equity
divestment
‒ Settlements
with tax authorities and expiry of statute of
limitations
|
EPS
|
$0.08
|
97% decrease
(84% at CER)
|
$5.29
|
32% increase
(37% at CER)
|
|
Further
details of differences between Reported and Core in Table
17
|
|
|
|
FY 2021
|
Q4 2021
|
|
||||
|
|
|
|
Actual
|
CER
|
|
Actual
|
CER
|
|
|
|
|
$m
|
% change
|
% change
|
$m
|
% change
|
% change
|
|
Tagrisso
|
Oncology
|
|
5,015
|
16
|
13
|
1,314
|
14
|
15
|
|
Imfinzi
|
|
|
2,412
|
18
|
16
|
634
|
14
|
15
|
|
Lynparza
|
|
|
2,748
|
23
|
21
|
1,029
|
25
|
26
|
|
Calquence
|
|
|
1,238
|
n/m
|
n/m
|
395
|
n/m
|
n/m
|
|
Enhertu
|
|
|
214
|
n/m
|
n/m
|
67
|
n/m
|
n/m
|
|
Farxiga
|
CVRM
|
|
3,005
|
53
|
49
|
849
|
45
|
46
|
|
Brilinta
|
|
|
1,472
|
(8)
|
(10)
|
348
|
(4)
|
(4)
|
|
Bydureon
|
|
|
385
|
(14)
|
(15)
|
91
|
(25)
|
(25)
|
|
Roxadustat
|
|
|
180
|
n/m
|
n/m
|
31
|
n/m
|
n/m
|
|
Lokelma
|
|
|
175
|
n/m
|
n/m
|
54
|
90
|
95
|
|
Symbicort
|
R&I
|
|
2,728
|
-
|
(2)
|
681
|
-
|
-
|
|
Fasenra
|
|
|
1,258
|
33
|
31
|
357
|
26
|
27
|
|
Pulmicort
|
|
|
962
|
(3)
|
(8)
|
248
|
(33)
|
(34)
|
|
Breztri
|
|
|
203
|
n/m
|
n/m
|
73
|
n/m
|
n/m
|
|
Soliris16
|
Rare
|
|
1,874
|
1
|
2
|
1,076
|
4
|
6
|
|
Ultomiris16
|
Disease16
|
|
688
|
27
|
29
|
391
|
24
|
26
|
|
Strensiq16
|
|
|
378
|
13
|
13
|
219
|
17
|
18
|
|
Vaxzevria
|
COVID-19
|
|
3,981
|
n/m
|
n/m
|
1,762
|
n/m
|
n/m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
FY 2021
|
Q4 2021
|
||||||
|
|
|
% of
|
Actual %
|
CER %
|
|
Actual %
|
CER %
|
|
|
|
$m
|
total
|
change
|
change
|
$m
|
change
|
change
|
|
Emerging Markets
|
|
12,281
|
33
|
41
|
36
|
3,663
|
63
|
61
|
|
US
|
|
12,228
|
33
|
38
|
38
|
3,923
|
64
|
64
|
|
Europe
|
|
8,050
|
22
|
45
|
40
|
2,872
|
57
|
58
|
|
Established Rest of World
|
|
4,858
|
13
|
37
|
37
|
1,553
|
64
|
72
|
|
Total
|
|
37,417
|
100
|
41
|
38
|
12,011
|
62
|
63
|
|
Event
|
Medicine
|
Indication / Trial
|
Event
|
Regulatory approvals
or other regulatory action
|
Saphnelo
|
Lupus (SLE[19])
|
CHMP[20] positive
opinion (EU)
|
Tezspire
|
Severe asthma
|
Approval (US)
|
|
Evusheld
|
COVID-19 prophylaxis
|
EUA (US)
|
|
Regulatory submissions, acceptances
|
Lynparza
|
Breast cancer (adjuvant, BRCAm[21])
|
Priority Review (US)
|
Lynparza
|
Breast cancer (adjuvant, BRCAm)
|
Regulatory submission (EU, JP)
|
|
Lynparza
|
Ovarian cancer (1st-line)
|
Regulatory submission (CN)
|
|
Lynparza
|
Prostate cancer (1st-line)
|
Regulatory submission (EU)
|
|
Enhertu
|
HER2+[22] breast
cancer (2nd-line)
|
Priority Review (US)
|
|
Enhertu
|
HER2+ breast cancer (2nd-line)
|
Regulatory submission (EU, JP)
|
|
Imfinzi +/-
tremelimumab
|
NSCLC[23] (1st-line)
|
Regulatory submission (US, EU, JP)
|
|
Koselugo
|
NF1-PN[24]
|
Regulatory submission (JP)
|
|
Ultomiris
|
Subcutaneous formulation in PNH[25]and
aHUS[26]
|
Regulatory submission (US)
|
|
Ultomiris
|
gMG[27]
|
Priority Review (US)
|
|
Major Phase III
data readouts, or
other significant developments
|
Vaxzevria /
AZD2816
|
COVID-19
|
Phase III primary endpoint met
|
Lynparza
|
Breast cancer (adjuvant, BRCAm)
|
Orphan Drug Designation (JP)
|
|
Lokelma
|
Chronic haemodialysis with hyperkalaemia
|
Fast Track Designation (US)
|
|
eplontersen
|
hATTR-PN[28] and
ATTR-CM[29]
|
Orphan Drug Designation (US)
|
Timing
|
Medicine
|
Indication / Trial
|
Event
|
|
Imfinzi
|
Biliary tract cancer (TOPAZ-1)
|
Regulatory submission
|
|
Imfinzi
|
NSCLC (1st-line) (PEARL)
|
Data readout
|
|
Imfinzi
|
Cervical cancer (CALLA)
|
Data readout
|
|
Imfinzi
|
NSCLC (unresectable, Stage III)(PACIFIC-2)
|
Data readout
|
|
Imfinzi +/-
tremelimumab
|
Liver cancer (1st-line) (HIMALAYA)
|
Regulatory submission
|
|
Lynparza
|
Breast cancer (adjuvant, BRCAm)
|
Regulatory decision (US)
|
|
Lynparza
|
Prostate cancer (1st-line)
|
Regulatory submission (US, JP)
|
|
Enhertu
|
Breast cancer (2nd-line, HER2+)
|
Regulatory decision (US)
|
|
Enhertu
|
Breast cancer (3rd-line, HER2-low)(DESTINY-Breast04)
|
Data readout, regulatory submission
|
|
Brilique
|
Stroke
|
Regulatory decision (CN)
|
H1 2022
|
Forxiga
|
Chronic kidney disease
|
Regulatory decision (CN)
|
|
Farxiga
|
HFpEF[30] (DELIVER)
|
Data readout
|
|
Fasenra
|
Nasal polyps
|
Regulatory decision (US)
|
|
Saphnelo
|
Lupus (SLE)
|
Regulatory decision (EU)
|
|
tezepelumab
|
Asthma
|
Regulatory decision (EU, JP)
|
|
PT027
|
Asthma
|
Regulatory submission (US)
|
|
Ultomiris
|
Subcutaneous formulation in PNH and aHUS
|
Regulatory submission (EU)
|
|
Ultomiris
|
NMOSD[31]
|
Data readout
|
|
Ultomiris
|
gMG
|
Regulatory decision (US)
|
|
Vaxzevria
|
COVID-19
|
Regulatory submission (US)
|
|
Evusheld
|
COVID-19 outpatient treatment
|
Regulatory submission (EU, JP)
|
|
nirsevimab
|
Respiratory syncytial virus
|
Regulatory submission
|
|
Tagrisso
|
NSCLC (adjuvant, EGFRm[32])
|
Regulatory decision (JP)
|
|
Imfinzi
|
NSCLC (unresectable, Stage III)
|
Regulatory submission
|
|
Imfinzi
|
NSCLC (1st-line)
|
Regulatory submission
|
|
Imfinzi
|
Cervical cancer
|
Regulatory submission
|
|
Imfinzi
|
Locoregional liver cancer (EMERALD-1)
|
Data readout, regulatory submission
|
H2 2022
|
Imfinzi
|
SCLC[33] (Limited-stage)
(ADRIATIC)
|
Data readout
|
|
Imfinzi +/-tremelimumab
|
NSCLC (1st-line)
|
Regulatory decision
|
|
Lynparza
|
Ovarian cancer (1st-line)
|
Regulatory decision (CN)
|
|
Lynparza
|
Prostate cancer (1st-line)
|
Regulatory decision (EU)
|
|
Lynparza
|
Breast cancer (adjuvant)
|
Regulatory decision (EU,JP)
|
|
Calquence
|
CLL[34]
|
Regulatory submission (JP)
|
|
Calquence
|
MCL[35] (1st-line)
(ECHO)
|
Data readout
|
|
Enhertu
|
Breast cancer (2nd-line, HER2+)
|
Regulatory decision (EU,JP)
|
|
Enhertu
|
Gastric cancer (2nd-line, HER2+)
|
Regulatory decision (EU)
|
|
Enhertu
|
Breast cancer (3rd-line, HER2+)(DESTINY-Breast02)
|
Data readout, regulatory submission
|
|
Farxiga
|
HFpEF
|
Regulatory submission
|
|
eplontersen
|
hATTR-PN (NEURO-TTRansform)
|
Data readout, regulatory submission
|
|
Fasenra
|
HES[36] (NATRON)
|
Data readout
|
H2 2022
|
Fasenra
|
EOE[37] (MESSINA)
|
Data readout
|
|
Ultomiris
|
Subcutaneous formulation in PNH and aHUS
|
Regulatory decision (US)
|
|
Ultomiris
|
gMG
|
Regulatory decision (EU,JP)
|
|
Ultomiris
|
NMOSD
|
Regulatory submission
|
|
ALXN1840
|
Wilson disease
|
Regulatory submission
|
|
acoramidis
|
ATTR-CM
|
Data readout
|
|
Koselugo
|
NF1-PN (SPRINT)
|
Regulatory submission (CN)
|
|
Koselugo
|
NF1-PN
|
Regulatory decision (JP)
|
|
Tagrisso
|
NSCLC (1st-line EGFRm) (FLAURA2)
|
Data readout, regulatory submission
|
|
Tagrisso
|
NSCLC (unresectable Stg. III, EGFRm) (LAURA)
|
Data readout, regulatory submission
|
|
Imfinzi
|
SCLC (Limited-stage)
|
Regulatory submission
|
|
Imfinzi
|
Bladder cancer (1st-line) (NILE)
|
Data readout, regulatory submission
|
|
Imfinzi
|
Bladder cancer (MI[38])
(NIAGARA)
|
Data readout, regulatory submission
|
|
Imfinzi
|
HCC[39] (adjuvant)
(EMERALD-2)
|
Data readout, regulatory submission
|
|
Imfinzi
|
NSCLC (Neoadjuvant) (AEGEAN)
|
Data readout, regulatory submission
|
|
Lynparza
|
Adjuvant breast cancer
|
Regulatory submission (CN)
|
2023
|
Lynparza
|
1st-line CRC[40] (LYNK-003)
|
Data readout, regulatory submission
|
|
Lynparza + Imfinzi
|
Ovarian cancer (1st-line) (DuO-O)
|
Data readout
|
|
Lynparza + Imfinzi
|
Endometrial cancer (1st-line) (DuO-E)
|
Data readout
|
|
Enhertu
|
Gastric cancer (HER2oe[41])(DESTINY-Gastric03)
|
Data readout
|
|
Enhertu
|
NSCLC (unresectable, HER2m) (DESTINY-Lung02)
|
Data readout
|
|
Enhertu
|
Breast cancer (2nd-line HER2-low) (DESTINY-Breast06)
|
Data readout
|
|
Calquence
|
CLL (Front line) (AC-CL-311)
|
Data readout
|
|
datopotamab deruxtecan
|
NSCLC (3rd-line) (TROPION-Lung01)
|
Data readout, regulatory submission
|
|
capivasertib
|
TNBC[42] (CAPitello-290)
|
Data readout, regulatory submission
|
|
capivasertib
|
Breast cancer (HR+/HER2-neg)(CAPitello-291)
|
Data readout, regulatory submission
|
|
camizestrant
|
HR+ HER2-neg BC (SERENA-6)
|
Data readout
|
|
Farxiga
|
Myocardial infarction (DAPA-MI)
|
Data readout
|
|
roxadustat
|
Anaemia in MDS[43]
|
Data readout
|
|
Fasenra
|
Eosinophilic oesophagitis
|
Regulatory submission
|
2023
|
Fasenra
|
EGPA[44]
(MANDARA)
|
Data readout, regulatory submission
|
|
Fasenra
|
Hyper-eosinophilic syndrome
|
Regulatory submission
|
|
Fasenra
|
Severe asthma (MIRACLE)
|
Data readout, regulatory submission (CN)
|
|
Fasenra
|
CRwNP[45] (ORCHID)
|
Data readout
|
|
Fasenra
|
Bullous pemphigoid (FJORD)
|
Data readout
|
|
Soliris
|
Guillain-Barre syndrome
|
Data readout (JP)
|
|
acoramidis
|
ATTR-CM
|
Data readout (JP)
|
|
danicopan
|
PNH with extravascular haemolysis
|
Data readout, regulatory submission
|
|
|
FY 2021
|
Q4 2021
|
||||||
|
|
|
% of
|
Actual %
|
CER %
|
|
% of
|
Actual %
|
CER %
|
|
|
$m
|
Total
|
change
|
change
|
$m
|
total
|
change
|
change
|
Oncology
|
|
13,663
|
37
|
19
|
17
|
3,919
|
33
|
20
|
21
|
BioPharmaceuticals: CVRM
|
|
8,034
|
21
|
13
|
9
|
2,007
|
17
|
8
|
8
|
BioPharmaceuticals: R&I
|
|
6,049
|
16
|
13
|
9
|
1,593
|
13
|
4
|
3
|
Rare Disease16
|
|
3,071
|
8
|
8
|
9
|
1,760
|
15
|
10
|
11
|
Other medicines
|
|
2,484
|
7
|
(6)
|
(7)
|
835
|
7
|
12
|
14
|
COVID-19
|
|
4,116
|
11
|
n/m
|
n/m
|
1,897
|
16
|
n/m
|
n/m
|
Total Revenue
|
|
37,417
|
100
|
41
|
38
|
12,011
|
100
|
62
|
63
|
|
|
FY 2021
|
Q4 2021
|
||||||
|
|
$m
|
% of total
|
Actual % change
|
CER% change
|
$m
|
% of total
|
Actual % change
|
CER % change
|
Oncology
|
|
13,048
|
35
|
20
|
18
|
3,455
|
29
|
19
|
20
|
- Tagrisso
|
|
5,015
|
13
|
16
|
13
|
1,314
|
11
|
14
|
15
|
- Imfinzi
|
|
2,412
|
6
|
18
|
16
|
634
|
5
|
14
|
15
|
- Lynparza
|
|
2,348
|
6
|
32
|
30
|
629
|
5
|
27
|
28
|
- Calquence
|
|
1,238
|
3
|
n/m
|
n/m
|
395
|
3
|
n/m
|
n/m
|
- Koselugo
|
|
108
|
-
|
n/m
|
n/m
|
34
|
-
|
92
|
94
|
- Enhertu
|
|
17
|
-
|
n/m
|
n/m
|
7
|
-
|
n/m
|
n/m
|
- Orpathys
|
|
16
|
-
|
n/m
|
n/m
|
6
|
-
|
n/m
|
n/m
|
- Zoladex
|
|
948
|
3
|
7
|
3
|
232
|
2
|
7
|
7
|
- Faslodex
|
|
431
|
1
|
(26)
|
(27)
|
101
|
1
|
(22)
|
(21)
|
- Iressa
|
|
183
|
-
|
(32)
|
(35)
|
35
|
-
|
(49)
|
(47)
|
- Casodex
|
|
143
|
-
|
(17)
|
(21)
|
22
|
-
|
(43)
|
(42)
|
- Arimidex
|
|
139
|
-
|
(25)
|
(27)
|
33
|
-
|
(9)
|
(11)
|
- Others
|
|
50
|
-
|
1
|
(1)
|
13
|
-
|
3
|
5
|
BioPharmaceuticals: CVRM
|
|
8,020
|
21
|
13
|
10
|
2,003
|
17
|
9
|
9
|
- Farxiga
|
|
3,000
|
8
|
53
|
49
|
848
|
7
|
45
|
46
|
- Brilinta
|
|
1,472
|
4
|
(8)
|
(10)
|
348
|
3
|
(4)
|
(4)
|
- Bydureon
|
|
385
|
1
|
(14)
|
(15)
|
91
|
1
|
(25)
|
(25)
|
- Onglyza
|
|
360
|
1
|
(23)
|
(26)
|
75
|
1
|
(28)
|
(29)
|
- Byetta
|
|
55
|
-
|
(19)
|
(19)
|
10
|
-
|
(44)
|
(42)
|
- Other diabetes
|
|
59
|
-
|
26
|
24
|
17
|
-
|
34
|
34
|
- Lokelma
|
|
175
|
-
|
n/m
|
n/m
|
54
|
-
|
90
|
95
|
- Roxadustat
|
|
174
|
-
|
n/m
|
n/m
|
30
|
-
|
n/m
|
n/m
|
- Crestor
|
|
1,096
|
3
|
(7)
|
(10)
|
259
|
2
|
(13)
|
(13)
|
- Seloken/Toprol-XL
|
|
951
|
3
|
16
|
10
|
202
|
2
|
1
|
(2)
|
- Atacand
|
|
97
|
-
|
(60)
|
(60)
|
21
|
-
|
(67)
|
(67)
|
- Others
|
|
196
|
1
|
3
|
(2)
|
48
|
-
|
4
|
3
|
BioPharmaceuticals: R&I
|
|
6,034
|
16
|
13
|
9
|
1,590
|
13
|
4
|
4
|
- Symbicort
|
|
2,728
|
7
|
-
|
(2)
|
681
|
6
|
-
|
-
|
- Fasenra
|
|
1,258
|
3
|
33
|
31
|
357
|
3
|
26
|
27
|
- Pulmicort
|
|
962
|
3
|
(3)
|
(8)
|
248
|
2
|
(33)
|
(34)
|
- Daliresp
|
|
227
|
1
|
5
|
4
|
59
|
-
|
8
|
8
|
- Breztri
|
|
203
|
1
|
n/m
|
n/m
|
73
|
1
|
n/m
|
n/m
|
- Bevespi
|
|
54
|
-
|
12
|
12
|
15
|
-
|
24
|
26
|
- Saphnelo
|
|
8
|
-
|
n/m
|
n/m
|
7
|
-
|
n/m
|
n/m
|
- Others
|
|
594
|
2
|
49
|
42
|
150
|
1
|
20
|
18
|
Rare Disease16
|
|
3,070
|
8
|
8
|
9
|
1,759
|
15
|
10
|
11
|
- Soliris16
|
|
1,874
|
5
|
1
|
2
|
1,076
|
9
|
4
|
6
|
- Ultomiris16
|
|
688
|
2
|
27
|
29
|
391
|
3
|
24
|
26
|
- Strensiq16
|
|
378
|
1
|
13
|
13
|
219
|
2
|
17
|
18
|
- Andexxa16
|
|
68
|
-
|
(3)
|
(3)
|
39
|
-
|
-
|
(1)
|
- Kanuma16
|
|
62
|
-
|
20
|
21
|
34
|
-
|
16
|
17
|
Other medicines
|
|
2,367
|
6
|
(8)
|
(10)
|
825
|
7
|
13
|
15
|
- Nexium
|
|
1,326
|
4
|
(11)
|
(12)
|
328
|
3
|
(13)
|
(10)
|
- Synagis
|
|
410
|
1
|
10
|
13
|
239
|
2
|
n/m
|
n/m
|
- FluMist
|
|
253
|
1
|
(14)
|
(17)
|
178
|
1
|
(1)
|
(4)
|
- Losec/Prilosec
|
|
180
|
-
|
(2)
|
(7)
|
41
|
-
|
7
|
6
|
- Seroquel
XR/IR
|
|
92
|
-
|
(21)
|
(20)
|
19
|
-
|
(3)
|
(2)
|
- Others
|
|
106
|
-
|
(16)
|
(19)
|
20
|
-
|
(48)
|
(49)
|
COVID-19
|
|
4,002
|
11
|
n/m
|
n/m
|
1,866
|
16
|
n/m
|
n/m
|
- Vaxzevria
|
|
3,917
|
10
|
n/m
|
n/m
|
1,781
|
15
|
n/m
|
n/m
|
- Evusheld
|
|
85
|
-
|
n/m
|
n/m
|
85
|
1
|
n/m
|
n/m
|
Product Sales
|
|
36,541
|
98
|
41
|
38
|
11,498
|
96
|
64
|
65
|
Collaboration Revenue
|
|
876
|
2
|
20
|
20
|
513
|
4
|
29
|
29
|
Total Revenue
|
|
37,417
|
100
|
41
|
38
|
12,011
|
100
|
62
|
63
|
|
|
FY 2021
|
Q4 2021
|
||||||
|
|
$m
|
% of total
|
Actual % change
|
CER % change
|
$m
|
% of total
|
Actual % change
|
CER % change
|
Lynparza: milestone
revenue
|
|
400
|
46
|
(13)
|
(13)
|
400
|
78
|
23
|
23
|
Enhertu: share of gross
profits
|
|
193
|
22
|
n/m
|
n/m
|
59
|
12
|
83
|
83
|
Roxadustat: share of gross profits
|
|
6
|
1
|
(81)
|
(83)
|
2
|
-
|
(87)
|
(87)
|
Other Collaboration Revenue
|
|
277
|
32
|
94
|
94
|
52
|
10
|
66
|
73
|
Total
|
|
876
|
100
|
20
|
20
|
513
|
100
|
29
|
29
|
|
|
FY 2021
|
Q4 2021
|
|||||
|
|
|
% of
|
Actual %
|
CER %
|
|
Actual %
|
CER %
|
|
|
$m
|
total
|
change
|
change
|
$m
|
change
|
change
|
Emerging Markets
|
|
12,281
|
33
|
41
|
36
|
3,663
|
63
|
61
|
- China
|
|
6,011
|
16
|
12
|
4
|
1,312
|
(4)
|
(8)
|
- Ex-China
|
|
6,270
|
17
|
88
|
89
|
2,351
|
n/m
|
n/m
|
US
|
|
12,228
|
33
|
38
|
38
|
3,923
|
64
|
64
|
Europe
|
|
8,050
|
22
|
45
|
40
|
2,872
|
57
|
58
|
Established RoW
|
|
4,858
|
13
|
37
|
37
|
1,553
|
64
|
72
|
- Japan
|
|
3,498
|
9
|
34
|
37
|
1,137
|
58
|
71
|
- Canada
|
|
772
|
2
|
28
|
19
|
236
|
62
|
54
|
- Other Established
RoW
|
|
588
|
2
|
90
|
76
|
180
|
n/m
|
n/m
|
Total
|
|
37,417
|
100
|
41
|
38
|
12,011
|
62
|
63
|
|
|
FY 2021
|
Q4 2021
|
|||||
|
|
|
% of
|
Actual %
|
CER %
|
|
Actual %
|
CER %
|
|
|
$m
|
total
|
change
|
change
|
$m
|
change
|
change
|
Oncology
|
|
3,223
|
26
|
11
|
6
|
785
|
18
|
15
|
BioPharmaceuticals: CVRM
|
|
3,785
|
31
|
17
|
12
|
869
|
10
|
8
|
BioPharmaceuticals: R&I
|
|
1,749
|
14
|
9
|
4
|
445
|
(19)
|
(21)
|
Rare Disease16
|
|
196
|
2
|
11
|
18
|
131
|
81
|
91
|
Other medicines
|
|
956
|
8
|
(1)
|
(4)
|
200
|
(17)
|
(18)
|
COVID-19
|
|
2,372
|
19
|
n/m
|
n/m
|
1,233
|
n/m
|
n/m
|
Total
|
|
12,281
|
100
|
41
|
36
|
3,663
|
63
|
61
|
|
|
FY 2021
|
Q4 2021
|
||||
|
|
|
Actual %
|
CER %
|
|
Actual %
|
CER %
|
|
|
$m
|
change
|
change
|
$m
|
change
|
change
|
Ex-China Emerging Markets
|
|
6,270
|
88
|
89
|
2,351
|
n/m
|
n/m
|
- Russia
|
|
445
|
42
|
45
|
138
|
80
|
71
|
- Brazil
|
|
973
|
n/m
|
n/m
|
523
|
n/m
|
n/m
|
- Ex-Brazil Latin America
|
|
1,132
|
n/m
|
n/m
|
467
|
n/m
|
n/m
|
- Ex-China Asia Pacific
|
|
2,526
|
n/m
|
n/m
|
891
|
n/m
|
n/m
|
- Middle East and Africa
|
|
1,194
|
17
|
20
|
332
|
30
|
38
|
|
|
FY 2021
|
FY 2020
|
Actual
|
CER
|
|
|
$m
|
$m
|
% change
|
% change
|
Total Revenue
|
|
37,417
|
26,617
|
41
|
38
|
- Product Sales
|
|
36,541
|
25,890
|
41
|
38
|
- Collaboration Revenue
|
|
876
|
727
|
20
|
20
|
Cost of
Sales
|
|
(12,437)
|
(5,299)
|
n/m
|
n/m
|
Gross Profit
|
|
24,980
|
21,318
|
17
|
17
|
Gross Profit Margin
|
|
66.0%
|
79.5%
|
-14
|
-13
|
Distribution
Expense
|
|
(446)
|
(399)
|
12
|
7
|
% Total Revenue
|
|
1.2%
|
1.5%
|
-
|
-
|
R&D
Expense
|
|
(9,736)
|
(5,991)
|
62
|
59
|
% Total Revenue
|
|
26.0%
|
22.5%
|
-4
|
-3
|
SG&A
Expense
|
|
(15,234)
|
(11,294)
|
35
|
32
|
% Total Revenue
|
|
40.7%
|
42.4%
|
+2
|
+2
|
Other
Operating Income & Expense
|
|
1,492
|
1,528
|
(2)
|
(4)
|
% Total Revenue
|
|
4.0%
|
5.7%
|
-2
|
-2
|
Operating Profit
|
|
1,056
|
5,162
|
(80)
|
(70)
|
Operating Margin
|
|
2.8%
|
19.4%
|
-17
|
-15
|
Net
Finance Expense
|
|
(1,257)
|
(1,219)
|
3
|
2
|
Joint
Ventures and Associates
|
|
(64)
|
(27)
|
n/m
|
n/m
|
(Loss)/Profit before tax
|
|
(265)
|
3,916
|
n/m
|
(93)
|
Taxation
|
|
380
|
(772)
|
n/m
|
n/m
|
Tax rate
|
|
143%
|
20%
|
|
|
Profit after tax
|
|
115
|
3,144
|
(96)
|
(83)
|
Earnings per share
|
|
$0.08
|
$2.44
|
(97)
|
(84)
|
|
|
Q4 2021
|
Q4 2020
|
Actual
|
CER
|
|
|
$m
|
$m
|
% change
|
% change
|
Total Revenue
|
|
12,011
|
7,410
|
62
|
63
|
- Product Sales
|
|
11,498
|
7,011
|
64
|
65
|
- Collaboration Revenue
|
|
513
|
399
|
29
|
29
|
Cost of Sales
|
|
(4,625)
|
(1,525)
|
n/m
|
n/m
|
Gross Profit
|
|
7,386
|
5,885
|
25
|
31
|
Gross Profit Margin
|
|
59.8%
|
78.2%
|
-18
|
-16
|
Distribution Expense
|
|
(124)
|
(109)
|
14
|
13
|
% Total Revenue
|
|
1.0%
|
1.5%
|
-
|
-
|
R&D Expense
|
|
(2,584)
|
(1,719)
|
50
|
50
|
% Total Revenue
|
|
21.5%
|
23.2%
|
2
|
2
|
SG&A Expense
|
|
(5,117)
|
(3,210)
|
59
|
59
|
% Total Revenue
|
|
42.6%
|
43.3%
|
1
|
1
|
Other Operating Income & Expense
|
|
147
|
640
|
(77)
|
(78)
|
% Total Revenue
|
|
1.2%
|
8.6%
|
-7
|
-7
|
Operating (Loss)/Profit
|
|
(292)
|
1,487
|
n/m
|
n/m
|
Operating Margin
|
|
-2.4%
|
20.1%
|
-22
|
-20
|
Net Finance Expense
|
|
(335)
|
(314)
|
7
|
8
|
Joint Ventures and Associates
|
|
(9)
|
(6)
|
53
|
51
|
(Loss)/Profit Before Tax
|
|
(636)
|
1,167
|
n/m
|
n/m
|
Taxation
|
|
290
|
(162)
|
n/m
|
n/m
|
Tax rate
|
|
46%
|
14%
|
|
|
(Loss)/Profit After Tax
|
|
(346)
|
1,005
|
n/m
|
n/m
|
(Loss)/Earnings per share
|
|
$(0.22)
|
$0.78
|
n/m
|
n/m
|
|
|
FY 2021
|
FY 2020
|
Actual
|
CER
|
|
|
$m
|
$m
|
% change
|
% change
|
Reported (Loss)/Profit Before Tax
|
|
(265)
|
3,916
|
n/m
|
(93)
|
Net Finance Expense
|
|
1,257
|
1,219
|
3
|
2
|
Joint Venture and Associates
|
|
64
|
27
|
n/m
|
n/m
|
Depreciation, Amortisation and Impairment
|
|
6,530
|
3,149
|
n/m
|
99
|
EBITDA
|
|
7,586
|
8,311
|
(9)
|
(6)
|
|
|
Q4 2021
|
Q4 2020
|
Actual
|
CER
|
|
|
$m
|
$m
|
% change
|
% change
|
Reported (Loss)/Profit Before Tax
|
|
(636)
|
1,167
|
n/m
|
n/m
|
Net Finance Expense
|
|
335
|
314
|
7
|
8
|
Joint Venture and Associates
|
|
9
|
6
|
53
|
51
|
Depreciation, Amortisation and Impairment
|
|
2,192
|
797
|
n/m
|
n/m
|
EBITDA
|
|
1,900
|
2,284
|
(17)
|
(8)
|
FY 2021
|
Reported
|
Restructuring
|
Intangible Asset Amortisation & Impairments
|
Acquisition of Alexion[60]
|
Other[61]
|
Core[62]
|
Core
% change
|
Reported% change
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
$m
|
Gross Profit
|
24,980
|
722
|
66
|
2,206
|
(1)
|
27,973
|
30
|
30
|
Gross Profit Margin
|
66.0%
|
|
|
|
|
74.2%
|
-6
|
-5
|
Distribution Expense
|
(446)
|
-
|
-
|
-
|
-
|
(446)
|
12
|
7
|
R&D Expense
|
(9,736)
|
223
|
1,496
|
28
|
2
|
(7,987)
|
36
|
33
|
SG&A Expense
|
(15,234)
|
338
|
3,584
|
207
|
1
|
(11,104)
|
19
|
15
|
Total Operating Expense
|
(25,416)
|
561
|
5,080
|
235
|
3
|
(19,537)
|
25
|
22
|
Other Operating Income & Expense
|
1,492
|
-
|
-
|
-
|
-
|
1,492
|
(3)
|
(4)
|
Operating Profit
|
1,056
|
1,283
|
5,146
|
2,441
|
2
|
9,928
|
35
|
41
|
Operating Margin
|
2.8%
|
|
|
|
|
26.5%
|
-1
|
+1
|
Net Finance Expense
|
(1,257)
|
-
|
-
|
-
|
395
|
(862)
|
10
|
11
|
Taxation
|
380
|
(249)
|
(1,024)
|
(531)
|
(70)
|
(1,494)
|
14
|
19
|
EPS
|
$0.08
|
$0.73
|
$2.91
|
$1.34
|
$0.23
|
$5.29
|
32
|
37
|
FY 2021
|
Reported
|
Restructuring
|
Intangible Asset Amortisation & Impairments
|
Acquisition of Alexion57
|
Other58
|
Core59
|
Core
% change
|
Reported% change
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
$m
|
Gross Profit
|
7,386
|
501
|
19
|
1,157
|
(3)
|
9,060
|
53
|
59
|
Gross Profit Margin
|
59.8%
|
|
|
|
|
74.3%
|
-4
|
-2
|
Distribution Expense
|
(124)
|
-
|
-
|
-
|
-
|
(124)
|
14
|
13
|
R&D Expense
|
(2,584)
|
68
|
101
|
18
|
1
|
(2,396)
|
40
|
40
|
SG&A Expense
|
(5,117)
|
166
|
1,607
|
41
|
(65)
|
(3,368)
|
19
|
18
|
Total Operating Expense
|
(7,825)
|
234
|
1,708
|
59
|
(64)
|
(5,888)
|
27
|
26
|
Other Operating Income & Expense
|
147
|
-
|
(1)
|
-
|
-
|
146
|
(77)
|
(78)
|
Operating Profit
|
(292)
|
735
|
1,726
|
1,216
|
(67)
|
3,318
|
75
|
94
|
Operating Margin
|
-2.4%
|
|
|
|
|
27.6%
|
+2
|
+5
|
Net Finance Expense
|
(335)
|
-
|
-
|
-
|
102
|
(233)
|
14
|
16
|
Taxation
|
290
|
(156)
|
(327)
|
(289)
|
(15)
|
(497)
|
67
|
88
|
EPS
|
$(0.22)
|
$0.37
|
$0.91
|
$0.60
|
$0.01
|
$1.67
|
56
|
74
|
|
|
FY 2021
|
FY 2020
|
Change
|
|
|
$m
|
$m
|
$m
|
Reported Operating Profit
|
|
1,056
|
5,162
|
(4,106)
|
Depreciation, Amortisation and Impairment
|
|
6,530
|
3,149
|
3,381
|
Decrease in Working Capital and Short-term Provisions
|
|
2,021
|
361
|
1,721
|
Gains on Disposal of Intangible Assets
|
|
(513)
|
(1,030)
|
517
|
Gains on Disposal of Investments in Associates and Joint
Ventures
|
|
(776)
|
-
|
(776)
|
Non-Cash and Other Movements
|
|
109
|
(548)
|
596
|
Interest Paid
|
|
(721)
|
(733)
|
12
|
Taxation Paid
|
|
(1,743)
|
(1,562)
|
(181)
|
Net Cash Inflow from Operating Activities
|
|
5,963
|
4,799
|
1,164
|
Net Cash (Outflow)/Inflow before Financing Activities
|
|
(5,095)
|
4,514
|
(9,609)
|
Net Cash Inflow/(Outflow) from Financing Activities
|
|
3,649
|
(2,203)
|
5,852
|
|
|
At 31 Dec 2021
|
At 31 Dec 2020
|
|
$m
|
$m
|
|
Cash and cash equivalents
|
|
6,329
|
7,832
|
Other investments
|
|
69
|
160
|
Cash and investments
|
|
6,398
|
7,992
|
Overdrafts and short-term borrowings
|
|
(387)
|
(658)
|
Lease liabilities
|
|
(987)
|
(681)
|
Current instalments of loans
|
|
(1,273)
|
(1,536)
|
Non-current instalments of loans
|
|
(28,134)
|
(17,505)
|
Interest-bearing loans and borrowings
(Gross Debt)
|
|
(30,781)
|
(20,380)
|
Net derivatives
|
|
61
|
278
|
Net Debt
|
|
(24,322)
|
(12,110)
|
|
|
FY 2021
|
FY 2020
|
|
$m
|
$m
|
|
Total revenue
|
|
-
|
-
|
Gross profit
|
|
-
|
-
|
Operating loss
|
|
(157)
|
(45)
|
Loss for the period
|
|
(773)
|
(663)
|
Transactions with subsidiaries that are not issuers or
guarantors
|
|
5,914
|
2,637
|
|
|
At 31 Dec 2021
|
At 31 Dec 2020
|
|
$m
|
$m
|
|
Current assets
|
|
8
|
26
|
Non-current assets
|
|
-
|
4
|
Current liabilities
|
|
(1,442)
|
(1,720)
|
Non-current liabilities
|
|
(25,646)
|
(17,161)
|
Amounts due from subsidiaries that are not issuers or
guarantors
|
|
11,510
|
7,011
|
Amounts due to subsidiaries that are not issuers or
guarantors
|
|
(293)
|
(290)
|
|
|
|
Average exchange
rates versus USD
|
|
Annual impact of 5%
strengthening in exchange rate versus USD ($m)[63]
|
||
Currency
|
Primary Relevance
|
|
FY
2021[64]
|
YTD
2022[65]
|
% change
|
Total Revenue
|
Core Operating Profit
|
CNY
|
Total Revenue
|
|
6.43
|
6.36
|
1
|
277
|
158
|
EUR
|
Total Revenue
|
|
0.85
|
0.88
|
(4)
|
317
|
160
|
JPY
|
Total Revenue
|
|
109.83
|
114.90
|
(5)
|
229
|
158
|
Other[66]
|
|
|
|
|
|
420
|
196
|
GBP
|
Operating Expense
|
|
0.73
|
0.74
|
(1)
|
61
|
(93)
|
SEK
|
Operating Expense
|
|
8.58
|
9.14
|
(7)
|
6
|
(82)
|
For the year ended 31 December
|
2021
|
2020
|
$m
|
$m
|
|
Total Revenue
|
37,417
|
26,617
|
Product Sales
|
36,541
|
25,890
|
Collaboration Revenue
|
876
|
727
|
Cost of Sales
|
(12,437)
|
(5,299)
|
Gross profit
|
24,980
|
21,318
|
Distribution costs
|
(446)
|
(399)
|
Research and development expense
|
(9,736)
|
(5,991)
|
Selling, general and administrative expense
|
(15,234)
|
(11,294)
|
Other operating income and expense
|
1,492
|
1,528
|
Operating profit
|
1,056
|
5,162
|
Finance income
|
43
|
87
|
Finance expense
|
(1,300)
|
(1,306)
|
Share of after tax losses in associates and joint
ventures
|
(64)
|
(27)
|
(Loss)/Profit before tax
|
(265)
|
3,916
|
Taxation
|
380
|
(772)
|
Profit for the period
|
115
|
3,144
|
|
|
|
Other comprehensive (loss)/income
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
Remeasurement of the defined benefit pension liability
|
626
|
(168)
|
Net (losses)/gains on equity investments measured at fair value
through other comprehensive income
|
(187)
|
938
|
Fair value movements related to own credit risk on bonds designated
as fair value through profit or loss
|
-
|
(1)
|
Tax on items that will not be reclassified to profit or
loss
|
105
|
(81)
|
|
544
|
688
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
Foreign exchange arising on consolidation
|
(483)
|
443
|
Foreign exchange arising on designated borrowings in net investment
hedges
|
(321)
|
573
|
Fair value movements on cash flow hedges
|
(167)
|
180
|
Fair value movements on cash flow hedges transferred to profit or
loss
|
208
|
(254)
|
Fair value movements on derivatives designated in net investment
hedges
|
34
|
8
|
(Costs)/gains of hedging
|
(6)
|
9
|
Tax on items that may be reclassified subsequently to profit or
loss
|
46
|
(39)
|
|
(689)
|
920
|
Other comprehensive (loss)/income for the period, net of
tax
|
(145)
|
1,608
|
Total comprehensive (loss)/income for the period
|
(30)
|
4,752
|
|
|
|
Profit attributable to:
|
|
|
Owners of the Parent
|
112
|
3,196
|
Non-controlling interests
|
3
|
(52)
|
|
115
|
3,144
|
Total comprehensive income attributable to:
|
|
|
Owners of the Parent
|
(33)
|
4,804
|
Non-controlling interests
|
3
|
(52)
|
|
(30)
|
4,752
|
Basic earnings per $0.25 Ordinary Share
|
$0.08
|
$2.44
|
Diluted earnings per $0.25 Ordinary Share
|
$0.08
|
$2.44
|
Weighted average number of Ordinary Shares in issue
(millions)
|
1,418
|
1,312
|
Diluted weighted average number of Ordinary Shares in issue
(millions)
|
1,427
|
1,313
|
For the quarter ended 31 December
|
2021
|
2020
|
$m
|
$m
|
|
Total Revenue
|
12,011
|
7,410
|
Product Sales
|
11,498
|
7,011
|
Collaboration Revenue
|
513
|
399
|
Cost of Sales
|
(4,625)
|
(1,525)
|
Gross profit
|
7,386
|
5,885
|
Distribution costs
|
(124)
|
(109)
|
Research and development expense
|
(2,584)
|
(1,719)
|
Selling, general and administrative expense
|
(5,117)
|
(3,210)
|
Other operating income and expense
|
147
|
640
|
Operating (loss)/profit
|
(292)
|
1,487
|
Finance income
|
1
|
7
|
Finance expense
|
(336)
|
(321)
|
Share of after tax losses in associates and joint
ventures
|
(9)
|
(6)
|
(Loss)/Profit before tax
|
(636)
|
1,167
|
Taxation
|
290
|
(162)
|
(Loss)/Profit for the period
|
(346)
|
1,005
|
|
|
|
Other comprehensive (loss)/income
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
Remeasurement of the defined benefit pension liability
|
34
|
23
|
Net losses on equity investments measured at fair value through
other comprehensive income
|
(331)
|
(36)
|
Fair value movements related to own credit risk on bonds designated
as fair value through profit or loss
|
(4)
|
-
|
Tax on items that will not be reclassified to profit or
loss
|
34
|
(11)
|
|
(267)
|
(24)
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
Foreign exchange arising on consolidation
|
(115)
|
564
|
Foreign exchange arising on designated borrowings in net investment
hedges
|
(46)
|
428
|
Fair value movements on cash flow hedges
|
(64)
|
178
|
Fair value movements on cash flow hedges transferred to profit or
loss
|
71
|
(139)
|
Fair value movements on derivatives designated in net investment
hedges
|
12
|
(31)
|
Costs of hedging
|
-
|
(1)
|
Tax on items that may be reclassified subsequently to profit or
loss
|
9
|
(46)
|
|
(133)
|
953
|
Other comprehensive (loss)/income for the period, net of
tax
|
(400)
|
929
|
Total comprehensive (loss)/income for the period
|
(746)
|
1,934
|
|
|
|
(Loss)/Profit attributable to:
|
|
|
Owners of the Parent
|
(347)
|
1,012
|
Non-controlling interests
|
1
|
(7)
|
|
(346)
|
1,005
|
Total comprehensive (loss)/income attributable to:
|
|
|
Owners of the Parent
|
(747)
|
1,940
|
Non-controlling interests
|
1
|
(6)
|
|
(746)
|
1,934
|
Basic earnings per $0.25 Ordinary Share
|
$(0.22)
|
$0.78
|
Diluted earnings per $0.25 Ordinary Share
|
$(0.22)
|
$0.78
|
Weighted average number of Ordinary Shares in issue
(millions)
|
1,547
|
1,312
|
Diluted weighted average number of Ordinary Shares in issue
(millions)[76]
|
1,547
|
1,313
|
|
At 31 Dec 2021
|
At 31 Dec2020
|
$m
|
$m
|
|
Assets
|
|
|
Non-current assets
|
|
|
Property, plant and equipment
|
9,183
|
8,251
|
Right-of-use assets
|
988
|
666
|
Goodwill
|
19,997
|
11,845
|
Intangible assets
|
42,387
|
20,947
|
Investments in associates and joint ventures
|
69
|
39
|
Other investments
|
1,168
|
1,108
|
Derivative financial instruments
|
102
|
171
|
Other receivables
|
895
|
720
|
Deferred tax assets
|
4,330
|
3,438
|
|
79,119
|
47,185
|
Current assets
|
|
|
Inventories
|
8,983
|
4,024
|
Trade and other receivables
|
9,644
|
7,022
|
Other investments
|
69
|
160
|
Derivative financial instruments
|
83
|
142
|
Intangible assets
|
105
|
-
|
Income tax receivable
|
663
|
364
|
Cash and cash equivalents
|
6,329
|
7,832
|
Assets held for sale
|
368
|
-
|
|
26,244
|
19,544
|
Total assets
|
105,363
|
66,729
|
|
|
|
Liabilities
|
|
|
Current liabilities
|
|
|
Interest-bearing loans and borrowings
|
(1,660)
|
(2,194)
|
Lease liabilities
|
(233)
|
(192)
|
Trade and other payables
|
(18,938)
|
(15,785)
|
Derivative financial instruments
|
(79)
|
(33)
|
Provisions
|
(768)
|
(976)
|
Income tax payable
|
(916)
|
(1,127)
|
|
(22,594)
|
(20,307)
|
Non-current liabilities
|
|
|
Interest-bearing loans and borrowings
|
(28,134)
|
(17,505)
|
Lease liabilities
|
(754)
|
(489)
|
Derivative financial instruments
|
(45)
|
(2)
|
Deferred tax liabilities
|
(6,206)
|
(2,918)
|
Retirement benefit obligations
|
(2,454)
|
(3,202)
|
Provisions
|
(956)
|
(584)
|
Other payables
|
(4,933)
|
(6,084)
|
|
(43,482)
|
(30,784)
|
Total liabilities
|
(66,076)
|
(51,091)
|
Net assets
|
39,287
|
15,638
|
Equity
|
|
|
Capital and reserves attributable to equity holders of the
Parent
|
|
|
Share capital
|
387
|
328
|
Share premium account
|
35,126
|
7,971
|
Other reserves
|
2,045
|
2,024
|
Retained earnings
|
1,710
|
5,299
|
|
39,268
|
15,622
|
Non-controlling interests
|
19
|
16
|
Total equity
|
39,287
|
15,638
|
|
Share capital
|
Share premium account
|
Other reserves
|
Retained earnings
|
Total attributable to owners of the parent
|
Non-controlling interests
|
Total equity
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
At 1 Jan 2020
|
328
|
7,941
|
2,046
|
2,812
|
13,127
|
1,469
|
14,596
|
Profit for the period
|
-
|
-
|
-
|
3,196
|
3,196
|
(52)
|
3,144
|
Other comprehensive income
|
-
|
-
|
-
|
1,608
|
1,608
|
-
|
1,608
|
Transfer to other reserves
|
-
|
-
|
(22)
|
1,423
|
1,401
|
(1,401)
|
-
|
Transactions with owners:
|
|
|
|
|
|
|
|
Dividends
|
-
|
-
|
-
|
(3,668)
|
(3,668)
|
-
|
(3,668)
|
Issue of Ordinary Shares
|
-
|
30
|
-
|
-
|
30
|
-
|
30
|
Share-based payments charge for the period
|
-
|
-
|
-
|
277
|
277
|
-
|
277
|
Settlement of share plan awards
|
-
|
-
|
-
|
(349)
|
(349)
|
-
|
(349)
|
Net movement
|
-
|
30
|
(22)
|
2,487
|
2,495
|
(1,453)
|
1,042
|
At 31 Dec 2020
|
328
|
7,971
|
2,024
|
5,299
|
15,622
|
16
|
15,638
|
At 1 Jan 2021
|
328
|
7,971
|
2,024
|
5,299
|
15,622
|
16
|
15,638
|
Profit for the period
|
-
|
-
|
-
|
112
|
112
|
3
|
115
|
Other comprehensive loss
|
-
|
-
|
-
|
(145)
|
(145)
|
-
|
(145)
|
Transfer to other reserves
|
-
|
-
|
21
|
(21)
|
-
|
-
|
-
|
Transactions with owners:
|
|
|
|
|
|
|
|
Dividends
|
-
|
-
|
-
|
(3,882)
|
(3,882)
|
-
|
(3,882)
|
Issue of Ordinary Shares
|
59
|
27,155
|
-
|
-
|
27,214
|
-
|
27,214
|
Share-based payments charge for the period
|
-
|
-
|
-
|
615
|
615
|
-
|
615
|
Settlement of share plan awards
|
-
|
-
|
-
|
(781)
|
(781)
|
-
|
(781)
|
Issue of replacement share awards upon acquisition
|
-
|
-
|
-
|
513
|
513
|
-
|
513
|
Net movement
|
59
|
27,155
|
21
|
(3,589)
|
23,646
|
3[77]
|
23,649
|
At 31 Dec 2021
|
387
|
35,126
|
2,045
|
1,710
|
39,268
|
19
|
39,287
|
For the year ended 31 December
|
2021
|
2020
|
$m
|
$m
|
|
Cash flows from operating activities
|
|
|
(Loss)/Profit before tax
|
(265)
|
3,916
|
Finance income and expense
|
1,257
|
1,219
|
Share of after tax losses of associates and joint
ventures
|
64
|
27
|
Depreciation, amortisation and impairment
|
6,530
|
3,149
|
Decrease in working capital and short-term provisions
|
2,021
|
361
|
Gains on disposal of intangible assets
|
(513)
|
(1,030)
|
Gains on disposal of investments in associates and joint
ventures
|
(776)
|
-
|
Fair value movements on contingent consideration arising from
business combinations
|
14
|
(272)
|
Non-cash and other movements
|
95
|
(276)
|
Cash generated from operations
|
8,427
|
7,094
|
Interest paid
|
(721)
|
(733)
|
Tax paid
|
(1,743)
|
(1,562)
|
Net cash inflow from operating activities
|
5,963
|
4,799
|
Cash flows from investing activities
|
|
|
Acquisition of subsidiaries, net of cash acquired
|
(9,263)
|
-
|
Payments upon vesting of employee share awards attributable to
business combinations
|
(211)
|
-
|
Payment of contingent consideration from business
combinations
|
(643)
|
(822)
|
Purchase of property, plant and equipment
|
(1,091)
|
(961)
|
Disposal of property, plant and equipment
|
13
|
106
|
Purchase of intangible assets
|
(1,109)
|
(1,645)
|
Disposal of intangible assets
|
587
|
951
|
Movement in profit-participation liability
|
20
|
40
|
Purchase of non-current asset investments
|
(184)
|
(119)
|
Disposal of non-current asset investments
|
9
|
1,381
|
Movement in short-term investments, fixed deposits and other
investing instruments
|
96
|
745
|
Payments to associates and joint ventures
|
(92)
|
(8)
|
Disposal of investments in associates and joint
ventures
|
776
|
-
|
Interest received
|
34
|
47
|
Net cash outflow from investing activities
|
(11,058)
|
(285)
|
Net cash (outflow)/inflow before financing activities
|
(5,095)
|
4,514
|
Cash flows from financing activities
|
|
|
Proceeds from issue of share capital
|
29
|
30
|
Issue of loans and borrowings
|
12,929
|
2,968
|
Repayment of loans and borrowings
|
(4,759)
|
(1,609)
|
Dividends paid
|
(3,856)
|
(3,572)
|
Hedge contracts relating to dividend payments
|
(29)
|
(101)
|
Repayment of obligations under leases
|
(240)
|
(207)
|
Movement in short-term borrowings
|
(276)
|
288
|
Payments to acquire non-controlling interests
|
(149)
|
-
|
Net cash inflow/(outflow) from financing activities
|
3,649
|
(2,203)
|
Net (decrease)/increase in cash and cash equivalents in the
period
|
(1,446)
|
2,311
|
Cash and cash equivalents at the beginning of the
period
|
7,546
|
5,223
|
Exchange rate effects
|
(62)
|
12
|
Cash and cash equivalents at the end of the period
|
6,038
|
7,546
|
Cash and cash equivalents consist of:
|
|
|
Cash and cash equivalents
|
6,329
|
7,832
|
Overdrafts
|
(291)
|
(286)
|
|
6,038
|
7,546
|
|
At 1 Jan 2021
|
Cash flow
|
Acquisitions
|
Non-cash & other
|
Exchange movements
|
At 31 Dec 2021
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
|
Non-current instalments of loans
|
(17,505)
|
(12,929)
|
(187)
|
2,244
|
243
|
(28,134)
|
Non-current instalments of leases
|
(489)
|
-
|
(228)
|
(52)
|
15
|
(754)
|
Total long-term debt
|
(17,994)
|
(12,929)
|
(415)
|
2,192
|
258
|
(28,888)
|
Current instalments of loans
|
(1,536)
|
4,781
|
(2,336)
|
(2,268)
|
86
|
(1,273)
|
Current instalments of leases
|
(192)
|
254
|
(34)
|
(269)
|
8
|
(233)
|
Bank collateral
|
(288)
|
195
|
-
|
-
|
-
|
(93)
|
Other short-term borrowings excluding overdrafts
|
(84)
|
81
|
-
|
-
|
-
|
(3)
|
Overdraft
|
(286)
|
(31)
|
-
|
-
|
26
|
(291)
|
Total current debt
|
(2,386)
|
5,280
|
(2,370)
|
(2,537)
|
120
|
(1,893)
|
Gross borrowings
|
(20,380)
|
(7,649)
|
(2,785)
|
(345)
|
378
|
(30,781)
|
Net derivative financial instruments
|
278
|
-
|
6
|
(223)
|
-
|
61
|
Net borrowings
|
(20,102)
|
(7,649)
|
(2,779)
|
(568)
|
378
|
(30,720)
|
Cash and cash equivalents
|
7,832
|
(5,501)
|
4,086
|
-
|
(88)
|
6,329
|
Other investments - current
|
160
|
(89)
|
-
|
-
|
(2)
|
69
|
Cash and investments
|
7,992
|
(5,590)
|
4,086
|
-
|
(90)
|
6,398
|
Net Debt
|
(12,110)
|
(13,239)
|
1,307
|
(568)
|
288
|
(24,322)
|
|
|
2021
|
2020
|
||
|
Diabetes alliance
|
Other
|
Total
|
Total
|
|
|
$m
|
$m
|
$m
|
$m
|
|
At 1 January
|
|
2,932
|
391
|
3,323
|
4,139
|
Settlements
|
|
(625)
|
(18)
|
(643)
|
(822)
|
Revaluations
|
|
42
|
(28)
|
14
|
(272)
|
Reclass to other payables
|
|
-
|
(55)
|
(55)
|
-
|
Discount unwind
|
|
195
|
31
|
226
|
278
|
At 31 December
|
|
2,544
|
321
|
2,865
|
3,323
|
|
Fair value
$m
|
Non-current assets
|
|
Property, plant and equipment
|
1,135
|
Right-of-use assets
|
263
|
Intangible assets
|
26,855
|
Other non-current assets
|
301
|
|
28,554
|
Current assets
|
|
Inventories
|
6,769
|
Trade and other receivables
|
2,096
|
Intangible assets
|
100
|
Cash and cash equivalents
|
4,086
|
|
13,051
|
Current liabilities
|
|
Interest-bearing loans and borrowings
|
(2,336)
|
Trade and other payables
|
(1,192)
|
Other current liabilities
|
(40)
|
|
(3,568)
|
Non-current liabilities
|
|
Lease liabilities
|
(228)
|
Deferred tax liabilities
|
(4,191)
|
Other non-current liabilities
|
(697)
|
|
(5,116)
|
|
|
Total net assets acquired
|
32,921
|
|
|
Less: non-controlling interests
|
(150)
|
Goodwill
|
8,287
|
Total fair value of consideration
|
41,058
|
|
|
Less: fair value of equity consideration
|
(27,196)
|
Less: fair value of replacement employee share
awards
|
(513)
|
Less: cash and cash equivalents acquired
|
(4,086)
|
Net cash outflow
|
9,263
|
|
Fair value
|
Useful lives
|
|
$m
|
Years
|
Launched medicines - C5 franchise (Soliris/Ultomiris)
|
18,480
|
6-15
|
Launched medicines - Strensiq, Kanuma, Andexxa
|
5,215
|
11-17
|
Medicines in development
|
2,760
|
Not amortised
|
Other intangibles
|
500
|
5-10
|
|
26,955
|
|
|
|
|
World
|
|
Emerging Markets
|
|
US
|
|
|
Europe
|
|
Established RoW
|
||
|
|
Actual
|
CER
|
|
Actual
|
CER
|
|
Actual
|
|
Actual
|
CER
|
|
Actual
|
CER
|
|
$m
|
% change
|
% change
|
$m
|
% change
|
% change
|
$m
|
% change
|
$m
|
% change
|
% change
|
$m
|
% change
|
% change
|
Oncology
|
13,048
|
20
|
18
|
3,223
|
11
|
6
|
5,359
|
26
|
2,484
|
28
|
22
|
1,982
|
13
|
13
|
Tagrisso
|
5,015
|
16
|
13
|
1,336
|
11
|
6
|
1,780
|
14
|
986
|
32
|
25
|
913
|
13
|
14
|
Imfinzi
|
2,412
|
18
|
16
|
277
|
76
|
68
|
1,245
|
5
|
485
|
31
|
25
|
405
|
23
|
23
|
Lynparza
|
2,348
|
32
|
30
|
384
|
45
|
41
|
1,087
|
24
|
618
|
42
|
35
|
259
|
29
|
28
|
Calquence
|
1,238
|
n/m
|
n/m
|
20
|
n/m
|
n/m
|
1,089
|
n/m
|
111
|
n/m
|
n/m
|
18
|
n/m
|
n/m
|
Koselugo
|
108
|
n/m
|
n/m
|
1
|
n/m
|
n/m
|
104
|
n/m
|
3
|
n/m
|
n/m
|
-
|
-
|
-
|
Enhertu
|
17
|
n/m
|
n/m
|
12
|
n/m
|
n/m
|
-
|
-
|
4
|
n/m
|
n/m
|
1
|
n/m
|
n/m
|
Orpathys
|
16
|
n/m
|
n/m
|
16
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Zoladex
|
948
|
7
|
3
|
619
|
10
|
5
|
13
|
n/m
|
147
|
5
|
(1)
|
169
|
(7)
|
(7)
|
Faslodex
|
431
|
(26)
|
(27)
|
167
|
(8)
|
(10)
|
30
|
(46)
|
113
|
(49)
|
(52)
|
121
|
(2)
|
(1)
|
Iressa
|
183
|
(32)
|
(35)
|
151
|
(31)
|
(35)
|
11
|
(23)
|
5
|
(58)
|
(60)
|
16
|
(26)
|
(26)
|
Casodex
|
143
|
(17)
|
(21)
|
105
|
(21)
|
(26)
|
-
|
-
|
3
|
(3)
|
6
|
35
|
(3)
|
(3)
|
Arimidex
|
139
|
(25)
|
(27)
|
106
|
(28)
|
(31)
|
-
|
-
|
4
|
5
|
7
|
29
|
(15)
|
(14)
|
Others
|
50
|
1
|
(1)
|
29
|
3
|
1
|
-
|
-
|
5
|
51
|
43
|
16
|
(16)
|
(15)
|
BioPharmaceuticals: CVRM
|
8,020
|
13
|
10
|
3,780
|
18
|
14
|
2,124
|
2
|
1,494
|
22
|
16
|
622
|
7
|
5
|
Farxiga
|
3,000
|
53
|
49
|
1,195
|
74
|
70
|
732
|
29
|
810
|
60
|
52
|
263
|
34
|
31
|
Brilinta
|
1,472
|
(8)
|
(10)
|
328
|
(29)
|
(31)
|
735
|
1
|
346
|
1
|
(4)
|
63
|
8
|
(1)
|
Bydureon
|
385
|
(14)
|
(15)
|
3
|
(25)
|
(26)
|
321
|
(16)
|
55
|
5
|
-
|
6
|
(40)
|
(44)
|
Onglyza
|
360
|
(23)
|
(26)
|
179
|
(11)
|
(14)
|
88
|
(47)
|
61
|
5
|
(1)
|
32
|
(29)
|
(33)
|
Byetta
|
55
|
(19)
|
(19)
|
12
|
61
|
75
|
26
|
(31)
|
11
|
(20)
|
(25)
|
6
|
(36)
|
(38)
|
Other diabetes
|
59
|
26
|
24
|
18
|
n/m
|
n/m
|
22
|
(12)
|
17
|
35
|
31
|
2
|
11
|
12
|
Lokelma
|
175
|
n/m
|
n/m
|
3
|
(44)
|
(48)
|
115
|
n/m
|
13
|
n/m
|
n/m
|
44
|
n/m
|
n/m
|
Roxadustat
|
174
|
n/m
|
n/m
|
174
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Crestor
|
1,096
|
(7)
|
(10)
|
775
|
4
|
-
|
80
|
(13)
|
52
|
(60)
|
(62)
|
189
|
(11)
|
(10)
|
Seloken/Toprol-XL
|
951
|
16
|
10
|
928
|
19
|
13
|
1
|
(89)
|
11
|
(33)
|
(33)
|
11
|
9
|
(3)
|
Atacand
|
97
|
(60)
|
(60)
|
28
|
(84)
|
(84)
|
4
|
(65)
|
65
|
87
|
86
|
-
|
n/m
|
n/m
|
Others
|
196
|
3
|
(2)
|
137
|
9
|
3
|
-
|
-
|
53
|
(7)
|
(8)
|
6
|
(21)
|
(25)
|
BioPharmaceuticals: Respiratory & Immunology
|
6,034
|
13
|
9
|
1,749
|
9
|
4
|
2,404
|
24
|
1,247
|
6
|
1
|
634
|
(2)
|
(5)
|
Symbicort
|
2,728
|
-
|
(2)
|
609
|
7
|
4
|
1,065
|
4
|
670
|
(3)
|
(8)
|
384
|
(12)
|
(17)
|
Fasenra
|
1,258
|
33
|
31
|
20
|
67
|
67
|
790
|
31
|
286
|
41
|
34
|
162
|
24
|
22
|
Pulmicort
|
962
|
(3)
|
(8)
|
770
|
(3)
|
(9)
|
72
|
1
|
73
|
-
|
(5)
|
47
|
(13)
|
(15)
|
Daliresp
|
227
|
5
|
4
|
4
|
-
|
(2)
|
207
|
9
|
15
|
(32)
|
(37)
|
1
|
(3)
|
(10)
|
Breztri
|
203
|
n/m
|
n/m
|
55
|
n/m
|
n/m
|
115
|
n/m
|
7
|
n/m
|
n/m
|
26
|
n/m
|
n/m
|
Bevespi
|
54
|
12
|
12
|
4
|
n/m
|
n/m
|
39
|
(11)
|
11
|
n/m
|
n/m
|
-
|
-
|
-
|
Saphnelo
|
8
|
n/m
|
n/m
|
-
|
-
|
-
|
8
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Others
|
594
|
49
|
42
|
287
|
41
|
32
|
108
|
n/m
|
185
|
5
|
-
|
14
|
1
|
(6)
|
Rare Disease*
|
3,070
|
8
|
9
|
196
|
11
|
18
|
1,828
|
8
|
682
|
7
|
9
|
364
|
7
|
11
|
Soliris*
|
1,874
|
1
|
2
|
170
|
1
|
8
|
1,068
|
4
|
439
|
(8)
|
(7)
|
197
|
8
|
11
|
Ultomiris*
|
688
|
27
|
29
|
9
|
n/m
|
n/m
|
381
|
20
|
169
|
73
|
74
|
129
|
4
|
11
|
Strensiq*
|
378
|
13
|
13
|
10
|
81
|
78
|
297
|
13
|
36
|
2
|
3
|
35
|
9
|
14
|
Andexxa*
|
68
|
(3)
|
(3)
|
-
|
n/m
|
n/m
|
50
|
(21)
|
18
|
7
|
6
|
-
|
n/m
|
n/m
|
Kanuma*
|
62
|
20
|
21
|
7
|
n/m
|
n/m
|
32
|
13
|
20
|
7
|
9
|
3
|
14
|
25
|
Other medicines
|
2,367
|
(8)
|
(10)
|
954
|
(2)
|
(5)
|
221
|
(39)
|
596
|
(17)
|
(19)
|
596
|
12
|
15
|
Nexium
|
1,326
|
(11)
|
(12)
|
705
|
(7)
|
(10)
|
128
|
(24)
|
62
|
(13)
|
(18)
|
431
|
(13)
|
(12)
|
Synagis
|
410
|
10
|
13
|
35
|
-
|
-
|
23
|
(51)
|
203
|
(38)
|
(37)
|
149
|
-
|
-
|
FluMist
|
253
|
(14)
|
(17)
|
2
|
15
|
2
|
27
|
(62)
|
222
|
1
|
(2)
|
2
|
(50)
|
(53)
|
Losec/Prilosec
|
180
|
(2)
|
(7)
|
152
|
-
|
(7)
|
1
|
(89)
|
26
|
32
|
31
|
1
|
(82)
|
(72)
|
Seroquel XR/IR
|
92
|
(21)
|
(20)
|
46
|
(17)
|
(15)
|
12
|
(30)
|
29
|
2
|
2
|
5
|
(71)
|
(67)
|
Others
|
106
|
(16)
|
(19)
|
14
|
n/m
|
n/m
|
30
|
(45)
|
54
|
(5)
|
(9)
|
8
|
(13)
|
(19)
|
COVID-19
|
4,002
|
n/m
|
n/m
|
2,259
|
n/m
|
n/m
|
64
|
n/m
|
1,101
|
n/m
|
n/m
|
578
|
n/m
|
n/m
|
Vaxzevria
|
3,917
|
n/m
|
n/m
|
2,240
|
n/m
|
n/m
|
64
|
n/m
|
1,035
|
n/m
|
n/m
|
578
|
n/m
|
n/m
|
Evusheld
|
85
|
n/m
|
n/m
|
19
|
n/m
|
n/m
|
-
|
-
|
66
|
n/m
|
n/m
|
-
|
-
|
-
|
Total Product Sales
|
36,541
|
41
|
38
|
12,161
|
40
|
36
|
12,000
|
39
|
7,604
|
50
|
44
|
4,776
|
36
|
36
|
|
World
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|||||||||
|
|
Actual
|
CER
|
|
Actual
|
CER
|
|
Actual
|
|
Actual
|
CER
|
|
Actual
|
CER
|
|
$m
|
% change
|
% change
|
$m
|
% change
|
% change
|
$m
|
% change
|
$m
|
% change
|
% change
|
$m
|
% change
|
% change
|
Oncology
|
3,455
|
19
|
20
|
785
|
18
|
15
|
1,488
|
27
|
661
|
15
|
17
|
521
|
6
|
12
|
Tagrisso
|
1,314
|
14
|
15
|
325
|
26
|
23
|
486
|
15
|
258
|
5
|
7
|
245
|
6
|
12
|
Imfinzi
|
634
|
14
|
15
|
65
|
47
|
44
|
330
|
10
|
138
|
19
|
21
|
101
|
7
|
14
|
Lynparza
|
629
|
27
|
28
|
103
|
49
|
46
|
294
|
20
|
161
|
30
|
32
|
71
|
21
|
28
|
Calquence
|
395
|
n/m
|
n/m
|
8
|
n/m
|
n/m
|
336
|
91
|
43
|
n/m
|
n/m
|
8
|
n/m
|
n/m
|
Koselugo
|
34
|
92
|
94
|
-
|
-
|
-
|
32
|
82
|
2
|
n/m
|
n/m
|
-
|
-
|
-
|
Enhertu
|
7
|
n/m
|
n/m
|
5
|
-
|
-
|
-
|
-
|
2
|
n/m
|
n/m
|
-
|
-
|
-
|
Orpathys
|
6
|
n/m
|
n/m
|
6
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Zoladex
|
232
|
7
|
7
|
154
|
15
|
12
|
2
|
n/m
|
35
|
(2)
|
(2)
|
41
|
(13)
|
(7)
|
Faslodex
|
101
|
(22)
|
(21)
|
44
|
15
|
14
|
6
|
(40)
|
20
|
(61)
|
(61)
|
31
|
(1)
|
7
|
Iressa
|
35
|
(49)
|
(47)
|
29
|
(50)
|
(51)
|
2
|
(52)
|
1
|
(45)
|
5
|
3
|
(31)
|
(38)
|
Casodex
|
22
|
(43)
|
(42)
|
13
|
(55)
|
(56)
|
-
|
-
|
-
|
n/m
|
n/m
|
9
|
(9)
|
-
|
Arimidex
|
33
|
(9)
|
(11)
|
26
|
(2)
|
(5)
|
-
|
-
|
-
|
n/m
|
n/m
|
7
|
(26)
|
(24)
|
Others
|
13
|
3
|
5
|
7
|
(9)
|
(9)
|
-
|
-
|
1
|
n/m
|
n/m
|
5
|
(8)
|
(11)
|
BioPharmaceuticals: CVRM
|
2,003
|
9
|
9
|
868
|
12
|
10
|
576
|
(1)
|
386
|
17
|
18
|
173
|
10
|
14
|
Farxiga
|
848
|
45
|
46
|
318
|
61
|
60
|
228
|
24
|
225
|
57
|
60
|
77
|
28
|
32
|
Brilinta
|
348
|
(4)
|
(4)
|
71
|
3
|
1
|
178
|
(9)
|
83
|
(2)
|
(1)
|
16
|
9
|
5
|
Bydureon
|
91
|
(25)
|
(25)
|
1
|
(28)
|
(43)
|
78
|
(26)
|
12
|
(14)
|
(13)
|
-
|
(88)
|
(79)
|
Onglyza
|
75
|
(28)
|
(29)
|
28
|
(40)
|
(41)
|
25
|
(20)
|
14
|
(10)
|
(11)
|
8
|
(27)
|
(29)
|
Byetta
|
10
|
(44)
|
(42)
|
2
|
n/m
|
n/m
|
5
|
(59)
|
2
|
(32)
|
(36)
|
1
|
(56)
|
(47)
|
Other diabetes
|
17
|
34
|
34
|
6
|
n/m
|
n/m
|
7
|
17
|
4
|
7
|
14
|
-
|
-
|
-
|
Lokelma
|
54
|
90
|
95
|
-
|
n/m
|
n/m
|
34
|
70
|
5
|
n/m
|
n/m
|
15
|
n/m
|
n/m
|
Roxadustat
|
30
|
n/m
|
n/m
|
30
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Crestor
|
259
|
(13)
|
(13)
|
178
|
(6)
|
(7)
|
21
|
-
|
9
|
(73)
|
(73)
|
51
|
(5)
|
1
|
Seloken/Toprol-XL
|
202
|
1
|
(2)
|
197
|
4
|
1
|
-
|
n/m
|
2
|
(57)
|
(57)
|
3
|
14
|
3
|
Atacand
|
21
|
(67)
|
(67)
|
3
|
(93)
|
(93)
|
-
|
(87)
|
18
|
36
|
33
|
-
|
n/m
|
n/m
|
Others
|
48
|
4
|
3
|
34
|
5
|
2
|
-
|
n/m
|
12
|
(2)
|
1
|
2
|
28
|
18
|
BioPharmaceuticals: Respiratory & Immunology
|
1,590
|
4
|
4
|
445
|
(19)
|
(21)
|
647
|
23
|
335
|
11
|
11
|
163
|
6
|
8
|
Symbicort
|
681
|
-
|
-
|
152
|
5
|
3
|
262
|
(2)
|
171
|
(1)
|
-
|
96
|
1
|
-
|
Fasenra
|
357
|
26
|
27
|
5
|
n/m
|
n/m
|
234
|
30
|
75
|
19
|
21
|
43
|
12
|
18
|
Pulmicort
|
248
|
(33)
|
(34)
|
193
|
(40)
|
(42)
|
19
|
5
|
23
|
31
|
32
|
13
|
(2)
|
-
|
Daliresp
|
59
|
8
|
8
|
1
|
24
|
(24)
|
54
|
11
|
4
|
(16)
|
(21)
|
-
|
-
|
-
|
Breztri
|
73
|
n/m
|
n/m
|
15
|
n/m
|
n/m
|
47
|
n/m
|
3
|
n/m
|
n/m
|
8
|
69
|
81
|
Bevespi
|
15
|
24
|
26
|
1
|
n/m
|
n/m
|
10
|
(3)
|
4
|
n/m
|
n/m
|
-
|
-
|
-
|
Saphnelo
|
7
|
n/m
|
n/m
|
-
|
-
|
-
|
7
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Others
|
150
|
20
|
18
|
78
|
(4)
|
(8)
|
14
|
n/m
|
55
|
25
|
26
|
3
|
69
|
62
|
Rare Disease†
|
1,759
|
10
|
11
|
131
|
81
|
91
|
1,043
|
8
|
380
|
3
|
5
|
205
|
6
|
12
|
Soliris†
|
1,076
|
4
|
6
|
117
|
71
|
82
|
608
|
4
|
240
|
(12)
|
(10)
|
111
|
7
|
11
|
Ultomiris†
|
391
|
24
|
26
|
4
|
n/m
|
n/m
|
214
|
15
|
100
|
67
|
68
|
73
|
5
|
14
|
Strensiq†
|
219
|
17
|
18
|
6
|
71
|
68
|
173
|
19
|
20
|
(1)
|
1
|
20
|
8
|
15
|
Andexxa†
|
39
|
-
|
(1)
|
-
|
-
|
-
|
30
|
(14)
|
9
|
n/m
|
n/m
|
-
|
-
|
-
|
Kanuma†
|
34
|
16
|
17
|
4
|
n/m
|
n/m
|
18
|
12
|
11
|
-
|
3
|
1
|
(27)
|
1
|
Other medicines
|
825
|
13
|
15
|
199
|
(18)
|
(18)
|
41
|
(34)
|
329
|
14
|
13
|
256
|
85
|
97
|
Nexium
|
328
|
(13)
|
(10)
|
129
|
(33)
|
(33)
|
30
|
(29)
|
15
|
23
|
24
|
154
|
19
|
27
|
Synagis
|
239
|
n/m
|
n/m
|
20
|
n/m
|
n/m
|
1
|
n/m
|
121
|
56
|
58
|
97
|
n/m
|
n/m
|
FluMist
|
178
|
(1)
|
(4)
|
1
|
(18)
|
(31)
|
4
|
(21)
|
171
|
1
|
(3)
|
2
|
(44)
|
(35)
|
Losec/Prilosec
|
41
|
7
|
6
|
36
|
9
|
6
|
-
|
(78)
|
5
|
44
|
44
|
-
|
-
|
-
|
Seroquel XR/IR
|
19
|
(3)
|
(2)
|
10
|
(33)
|
(31)
|
-
|
(90)
|
8
|
6
|
6
|
1
|
(19)
|
(1)
|
Others
|
20
|
(48)
|
(49)
|
3
|
n/m
|
n/m
|
6
|
(67)
|
9
|
(49)
|
(49)
|
2
|
(48)
|
(50)
|
COVID-19
|
1,866
|
n/m
|
n/m
|
1,202
|
n/m
|
n/m
|
64
|
n/m
|
365
|
n/m
|
n/m
|
235
|
n/m
|
n/m
|
Vaxzevria
|
1,781
|
n/m
|
n/m
|
1,183
|
n/m
|
n/m
|
64
|
n/m
|
299
|
n/m
|
n/m
|
235
|
n/m
|
n/m
|
Evusheld
|
85
|
n/m
|
n/m
|
19
|
n/m
|
n/m
|
-
|
-
|
66
|
n/m
|
n/m
|
-
|
-
|
-
|
Total Product Sales
|
11,498
|
64
|
65
|
3,630
|
63
|
61
|
3,859
|
65
|
2,456
|
64
|
66
|
1,553
|
65
|
73
|
|
|
|
Q1 2021
|
|
|
Q2 2021
|
|
|
Q3 2021
|
|
|
Q4 2021
|
|
|
Actual
|
CER
|
|
Actual
|
CER
|
|
Actual
|
CER
|
|
Actual
|
CER
|
|
$m
|
% change
|
% change
|
$m
|
% change
|
% change
|
$m
|
% change
|
% change
|
$m
|
% change
|
% change
|
Oncology
|
2,981
|
3
|
1
|
3,286
|
10
|
11
|
3,326
|
1
|
2
|
3,455
|
4
|
5
|
Tagrisso
|
1,149
|
(1)
|
(3)
|
1,306
|
14
|
14
|
1,247
|
(5)
|
(4)
|
1,314
|
5
|
6
|
Imfinzi
|
556
|
-
|
(1)
|
604
|
9
|
10
|
618
|
2
|
3
|
634
|
3
|
4
|
Lynparza
|
543
|
9
|
8
|
588
|
8
|
9
|
588
|
-
|
1
|
629
|
7
|
8
|
Calquence
|
209
|
15
|
15
|
280
|
34
|
34
|
354
|
26
|
26
|
395
|
12
|
12
|
Koselugo
|
21
|
23
|
23
|
26
|
23
|
22
|
26
|
-
|
2
|
34
|
27
|
27
|
Enhertu
|
1
|
n/m
|
n/m
|
3
|
n/m
|
n/m
|
5
|
64
|
63
|
7
|
42
|
41
|
Orpathys
|
-
|
-
|
-
|
-
|
-
|
-
|
10
|
n/m
|
n/m
|
6
|
(39)
|
(40)
|
Zoladex
|
221
|
2
|
-
|
244
|
10
|
11
|
250
|
2
|
3
|
232
|
(7)
|
(5)
|
Faslodex
|
122
|
(6)
|
(8)
|
105
|
(14)
|
(12)
|
103
|
(2)
|
(2)
|
101
|
(1)
|
-
|
Iressa
|
61
|
(9)
|
(11)
|
47
|
(23)
|
(22)
|
41
|
(11)
|
(14)
|
35
|
(16)
|
(11)
|
Casodex
|
42
|
7
|
5
|
41
|
(2)
|
(1)
|
38
|
(7)
|
(8)
|
22
|
(42)
|
(38)
|
Arimidex
|
44
|
22
|
18
|
29
|
(34)
|
(33)
|
33
|
16
|
19
|
33
|
(2)
|
(7)
|
Others
|
12
|
(4)
|
(6)
|
13
|
13
|
11
|
13
|
(5)
|
(4)
|
13
|
(1)
|
1
|
BioPharmaceuticals: CVRM
|
1,912
|
4
|
1
|
2,023
|
6
|
6
|
2,082
|
3
|
3
|
2,003
|
(4)
|
(3)
|
Farxiga
|
624
|
6
|
4
|
732
|
17
|
18
|
796
|
9
|
9
|
848
|
7
|
9
|
Brilinta
|
374
|
3
|
1
|
375
|
-
|
1
|
375
|
-
|
1
|
348
|
(7)
|
(7)
|
Bydureon
|
103
|
(16)
|
(17)
|
95
|
(8)
|
(7)
|
95
|
1
|
2
|
91
|
(4)
|
(5)
|
Onglyza
|
101
|
(3)
|
(6)
|
99
|
(2)
|
(2)
|
84
|
(15)
|
(15)
|
75
|
(11)
|
(10)
|
Byetta
|
16
|
(14)
|
(15)
|
16
|
(4)
|
(7)
|
13
|
(15)
|
(7)
|
10
|
(21)
|
(22)
|
Other diabetes
|
13
|
7
|
1
|
15
|
14
|
14
|
14
|
(9)
|
(4)
|
17
|
21
|
17
|
Roxadustat
|
39
|
n/m
|
n/m
|
51
|
32
|
32
|
55
|
7
|
7
|
30
|
(45)
|
(46)
|
Lokelma
|
33
|
16
|
18
|
39
|
21
|
21
|
49
|
25
|
26
|
54
|
9
|
10
|
Crestor
|
274
|
(8)
|
(9)
|
265
|
(3)
|
(3)
|
298
|
12
|
13
|
259
|
(13)
|
(12)
|
Seloken/Toprol-XL
|
250
|
25
|
21
|
266
|
6
|
7
|
234
|
(12)
|
(13)
|
202
|
(13)
|
(13)
|
Atacand
|
34
|
(45)
|
(45)
|
23
|
(35)
|
(32)
|
19
|
(15)
|
(18)
|
21
|
9
|
8
|
Others
|
51
|
12
|
10
|
47
|
(7)
|
(10)
|
50
|
6
|
7
|
48
|
(4)
|
(4)
|
BioPharmaceuticals: Respiratory & Immunology
|
1,541
|
1
|
(1)
|
1,420
|
(8)
|
(7)
|
1,483
|
4
|
5
|
1,590
|
7
|
8
|
Symbicort
|
691
|
2
|
-
|
680
|
(2)
|
(1)
|
676
|
(1)
|
-
|
681
|
1
|
1
|
Fasenra
|
260
|
(8)
|
(9)
|
320
|
23
|
23
|
322
|
1
|
1
|
357
|
11
|
12
|
Pulmicort
|
330
|
(10)
|
(13)
|
167
|
(50)
|
(49)
|
217
|
30
|
30
|
248
|
14
|
15
|
Daliresp
|
60
|
11
|
10
|
54
|
(10)
|
(9)
|
54
|
-
|
(2)
|
59
|
9
|
10
|
Breztri
|
27
|
n/m
|
n/m
|
56
|
n/m
|
n/m
|
47
|
(15)
|
(15)
|
73
|
54
|
55
|
Bevespi
|
13
|
7
|
8
|
13
|
1
|
3
|
13
|
(1)
|
(2)
|
15
|
15
|
18
|
Saphnelo
|
-
|
-
|
-
|
-
|
-
|
-
|
1
|
n/m
|
n/m
|
7
|
n/m
|
n/m
|
Others
|
160
|
28
|
25
|
130
|
(19)
|
(19)
|
153
|
17
|
19
|
150
|
(2)
|
(2)
|
Rare Disease‡
|
-
|
-
|
-
|
-
|
-
|
-
|
1,311
|
(2)
|
(1)
|
1,759
|
4
|
6
|
Soliris‡
|
-
|
-
|
-
|
-
|
-
|
-
|
798
|
(6)
|
(4)
|
1,076
|
4
|
7
|
Ultomiris‡
|
-
|
-
|
-
|
-
|
-
|
-
|
297
|
7
|
8
|
391
|
4
|
5
|
Strensiq‡
|
-
|
-
|
-
|
-
|
-
|
-
|
159
|
(2)
|
(2)
|
219
|
8
|
9
|
Andexxa‡
|
-
|
-
|
-
|
-
|
-
|
-
|
29
|
5
|
6
|
39
|
1
|
-
|
Kanuma‡
|
-
|
-
|
-
|
-
|
-
|
-
|
28
|
9
|
9
|
34
|
(7)
|
(4)
|
Other medicines
|
548
|
(25)
|
(26)
|
454
|
(17)
|
(16)
|
539
|
19
|
20
|
825
|
53
|
55
|
Nexium
|
403
|
7
|
5
|
336
|
(17)
|
(15)
|
259
|
(23)
|
(23)
|
328
|
27
|
31
|
Synagis
|
24
|
(69)
|
(69)
|
24
|
1
|
1
|
122
|
n/m
|
n/m
|
239
|
97
|
98
|
FluMist
|
2
|
(99)
|
(99)
|
1
|
(51)
|
(71)
|
72
|
n/m
|
n/m
|
178
|
n/m
|
n/m
|
Losec/Prilosec
|
54
|
39
|
36
|
46
|
(14)
|
(15)
|
38
|
(18)
|
(17)
|
41
|
9
|
11
|
Seroquel XR/IR
|
29
|
51
|
38
|
21
|
(29)
|
(22)
|
24
|
17
|
14
|
19
|
(22)
|
(23)
|
Others
|
36
|
(6)
|
(4)
|
26
|
(28)
|
(32)
|
24
|
(8)
|
(5)
|
20
|
(16)
|
(17)
|
COVID-19
|
275
|
n/m
|
n/m
|
862
|
n/m
|
n/m
|
1,000
|
16
|
18
|
1,866
|
87
|
88
|
Vaxzevria
|
275
|
n/m
|
n/m
|
862
|
n/m
|
n/m
|
1,000
|
16
|
18
|
1,781
|
78
|
79
|
Evusheld
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
85
|
n/m
|
n/m
|
Total Product Sales
|
7,257
|
4
|
1
|
8,045
|
11
|
12
|
9,741
|
21
|
22
|
11,498
|
18
|
19
|
|
Q1 2020
|
Q2 2020
|
Q3 2020
|
Q4 2020
|
||||||||
|
|
Actual
|
CER
|
|
Actual
|
CER
|
|
Actual
|
CER
|
|
Actual
|
CER
|
|
$m
|
% change
|
% change
|
$m
|
% change
|
% change
|
$m
|
% change
|
% change
|
$m
|
% change
|
% change
|
Oncology
|
2,502
|
10
|
10
|
2,609
|
4
|
6
|
2,831
|
8
|
6
|
2,908
|
3
|
2
|
Tagrisso
|
982
|
11
|
11
|
1,034
|
5
|
7
|
1,155
|
12
|
9
|
1,157
|
-
|
(1)
|
Imfinzi
|
462
|
9
|
9
|
492
|
6
|
8
|
533
|
8
|
6
|
555
|
4
|
3
|
Lynparza
|
397
|
13
|
13
|
419
|
5
|
7
|
464
|
11
|
8
|
496
|
7
|
6
|
Calquence
|
88
|
58
|
58
|
107
|
21
|
23
|
145
|
36
|
35
|
182
|
25
|
25
|
Koselugo
|
-
|
-
|
-
|
7
|
n/m
|
n/m
|
13
|
75
|
75
|
17
|
34
|
34
|
Zoladex
|
225
|
15
|
15
|
217
|
(3)
|
-
|
230
|
6
|
3
|
216
|
(6)
|
(7)
|
Faslodex
|
166
|
-
|
-
|
146
|
(12)
|
(9)
|
138
|
(5)
|
(8)
|
130
|
(6)
|
(7)
|
Iressa
|
77
|
(3)
|
(4)
|
70
|
(9)
|
(7)
|
54
|
(23)
|
(24)
|
67
|
24
|
19
|
Arimidex
|
50
|
(1)
|
(2)
|
58
|
17
|
16
|
42
|
(28)
|
(27)
|
36
|
(14)
|
(16)
|
Casodex
|
42
|
(2)
|
(3)
|
47
|
14
|
12
|
44
|
(7)
|
(8)
|
39
|
(11)
|
(14)
|
Others
|
13
|
(52)
|
(52)
|
12
|
(11)
|
(1)
|
13
|
4
|
3
|
13
|
2
|
2
|
BioPharmaceuticals: CVRM
|
1,701
|
(5)
|
(5)
|
1,759
|
3
|
6
|
1,794
|
2
|
-
|
1,842
|
3
|
1
|
Farxiga
|
405
|
(3)
|
(3)
|
443
|
9
|
13
|
525
|
19
|
16
|
586
|
11
|
10
|
Brilinta
|
408
|
(5)
|
(5)
|
437
|
7
|
9
|
385
|
(12)
|
(13)
|
363
|
(6)
|
(6)
|
Onglyza
|
141
|
8
|
8
|
115
|
(19)
|
(17)
|
110
|
(6)
|
(6)
|
105
|
(4)
|
(5)
|
Bydureon
|
100
|
(28)
|
(28)
|
116
|
16
|
17
|
109
|
(5)
|
(7)
|
122
|
12
|
11
|
Byetta
|
20
|
(24)
|
(24)
|
15
|
(28)
|
(28)
|
15
|
1
|
4
|
19
|
26
|
24
|
Other diabetes
|
13
|
(22)
|
(22)
|
10
|
(21)
|
(19)
|
11
|
9
|
6
|
12
|
11
|
15
|
Lokelma
|
11
|
42
|
42
|
17
|
56
|
58
|
21
|
22
|
26
|
28
|
37
|
28
|
Crestor
|
301
|
2
|
1
|
281
|
(7)
|
(4)
|
300
|
7
|
5
|
298
|
(1)
|
(4)
|
Seloken/Toprol-XL
|
177
|
(6)
|
(6)
|
218
|
23
|
27
|
225
|
4
|
3
|
200
|
(11)
|
(13)
|
Atacand
|
66
|
11
|
12
|
59
|
(11)
|
(5)
|
54
|
(9)
|
(12)
|
63
|
16
|
14
|
Others
|
59
|
(21)
|
(22)
|
48
|
(18)
|
(16)
|
39
|
(19)
|
(22)
|
46
|
18
|
17
|
BioPharmaceuticals: Respiratory & Immunology
|
1,551
|
1
|
1
|
1,117
|
(28)
|
(26)
|
1,161
|
4
|
1
|
1,528
|
32
|
29
|
Symbicort
|
790
|
11
|
11
|
653
|
(17)
|
(15)
|
599
|
(8)
|
(11)
|
680
|
13
|
13
|
Pulmicort
|
380
|
(8)
|
(9)
|
97
|
(74)
|
(73)
|
151
|
56
|
49
|
368
|
n/m
|
n/m
|
Fasenra
|
199
|
(3)
|
(3)
|
227
|
14
|
15
|
240
|
5
|
4
|
283
|
18
|
17
|
Daliresp
|
53
|
(8)
|
(8)
|
53
|
(1)
|
(3)
|
57
|
8
|
11
|
54
|
(4)
|
(6)
|
Bevespi
|
12
|
9
|
9
|
10
|
(19)
|
(21)
|
14
|
47
|
46
|
12
|
(16)
|
(17)
|
Breztri
|
4
|
n/m
|
n/m
|
7
|
58
|
64
|
10
|
45
|
48
|
6
|
(39)
|
(38)
|
Others
|
113
|
(16)
|
(17)
|
70
|
(38)
|
(36)
|
90
|
27
|
22
|
125
|
39
|
35
|
Other medicines
|
557
|
(15)
|
(15)
|
563
|
1
|
4
|
734
|
30
|
27
|
733
|
-
|
(2)
|
Nexium
|
338
|
(4)
|
(4)
|
377
|
12
|
14
|
401
|
6
|
4
|
377
|
(6)
|
(7)
|
Synagis
|
85
|
35
|
35
|
90
|
6
|
7
|
118
|
31
|
29
|
78
|
(34)
|
(33)
|
FluMist
|
-
|
n/m
|
n/m
|
-
|
n/m
|
n/m
|
116
|
n/m
|
n/m
|
179
|
55
|
50
|
Losec/Prilosec
|
54
|
18
|
17
|
45
|
(15)
|
(15)
|
45
|
-
|
-
|
39
|
(15)
|
(18)
|
Seroquel XR/IR
|
36
|
(12)
|
(12)
|
27
|
(26)
|
(23)
|
35
|
32
|
29
|
19
|
(45)
|
(42)
|
Others
|
44
|
(71)
|
(70)
|
24
|
(46)
|
(42)
|
19
|
(17)
|
(19)
|
41
|
n/m
|
n/m
|
Total Product Sales
|
6,311
|
1
|
1
|
6,048
|
(4)
|
(2)
|
6,520
|
8
|
6
|
7,011
|
8
|
6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
FY 2021
|
FY 2020
|
FY 2019
|
|
|
$m
|
$m
|
$m
|
Initial Collaboration Revenue
|
|
|
|
|
Nexium (Japan)
|
|
75
|
-
|
-
|
Ongoing Collaboration Revenue
|
|
|
|
|
Lynparza: regulatory
milestones
|
|
-
|
160
|
60
|
Lynparza: sales
milestones
|
|
400
|
300
|
450
|
Lynparza/Koselugo: option payments
|
|
-
|
-
|
100
|
Crestor (Spain)
|
|
-
|
-
|
39
|
Enhertu: share of gross
profits
|
|
193
|
94
|
-
|
Roxadustat: share of gross profits
|
|
6
|
30
|
-
|
Royalty income
|
|
138
|
62
|
62
|
Other Ongoing Collaboration Revenue
|
|
64
|
81
|
108
|
Total
|
|
876
|
727
|
819
|
|
|
FY 2021
|
FY 2020
|
FY 2019
|
|
$m
|
$m
|
$m
|
|
Divestment of Viela Bio, Inc. shareholding
|
|
776
|
-
|
-
|
Crestor (Europe ex-UK and
Spain)
|
|
317
|
-
|
-
|
Late stage small-molecule antibiotics assets (ex-US)
|
|
100
|
-
|
75
|
Hypertension medicines (ex-US, India and Japan)
|
|
-
|
350
|
-
|
Monetisation of an asset previously licensed
|
|
-
|
120
|
-
|
Brazikumab licence termination funding
|
|
99
|
107
|
-
|
Inderal, Tenormin, Seloken and Omepral (Japan)
|
|
-
|
51
|
-
|
Synagis (US)
|
|
-
|
-
|
515
|
Losec (ex-China, Japan, US
and Mexico)
|
|
-
|
-
|
243
|
Seroquel and Seroquel XR (US, Canada, Europe and
Russia)
|
|
-
|
-
|
213
|
Arimidex and Casodex (various countries)
|
|
-
|
-
|
181
|
Nexium (Europe)
and Vimovo (ex-US)
|
|
-
|
54
|
-
|
Atacand
|
|
-
|
400
|
-
|
Other
|
|
200
|
446
|
314
|
Total
|
|
1,492
|
1,528
|
1,541
|
|
|
|
|
Registered office
|
Registrar and transfer office
|
Swedish Central Securities Depository
|
US depositary
Deutsche Bank Trust Company Americas
|
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge
CB2 0AA
|
Equiniti Limited
Aspect House
Spencer Road
Lancing
West Sussex
BN99 6DA
|
Euroclear Sweden AB PO Box 191
SE-101 23 Stockholm
|
American Stock Transfer
6201 15th Avenue
Brooklyn
NY 11219
|
United Kingdom
|
United Kingdom
|
Sweden
|
United States
|
|
|
|
|
+44 (0) 20 3749 5000
|
0800 389 1580
|
+46 (0) 8 402 9000
|
+1 (888) 697 8018
|
|
+44 (0) 121 415 7033
|
|
+1 (718) 921 8137
|
|
|
|
db@astfinancial.com
|
|
AstraZeneca
PLC
|
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|